PMID- 16781487
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20160422
IS  - 1521-6926 (Print)
IS  - 1521-6926 (Linking)
VI  - 19
IP  - 3
DP  - 2006
TI  - Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes 
      and myeloproliferative disorders.
PG  - 519-33
AB  - Hemopoietic cell transplantation (HCT) is presently the only therapy with 
      curative potential for myelodysplastic syndromes (MDS) and myeloproliferative 
      disorders (MPD). Among patients with less advanced MDS, 3-year survival figures 
      of 65-80% are achieved with human leukocyte antigen (HLA)-identical related and 
      unrelated donors. The probability of relapse is less than 5%. Among patients with 
      advanced MDS (> or = 5% marrow blasts), about 35-50% of patients transplanted 
      from related donors, and 25-40% transplanted from unrelated donors are surviving 
      in remission beyond 3 years. The incidence of post-transplant relapse is 10-35%. 
      Criteria of the International Prognostic Scoring System (IPSS) predict relapse 
      and survival following HCT. In patients with myelofibrosis, allogeneic 
      transplantation is successful in 50-80%, if performed during the fibrosis stage. 
      The success rate declines to 25-40%, if the transplant is performed after 
      leukemic transformation has occurred. About 40% of patients with chronic 
      myelomonocytic leukemia survive in remission after transplantation. Results 
      obtained with low/reduced-intensity conditioning regimens are encouraging because 
      of a low incidence of early mortality. However, retrospective analyses comparing 
      low intensity and conventional conditioning regimens have yielded inconclusive 
      results regarding long-term outcome. Co-morbid conditions present at the time of 
      transplantation have a major negative effect on transplant outcome. Controlled 
      prospective trials are needed.
FAU - Scott, Bart
AU  - Scott B
AD  - Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, P.O. 
      Box 19024, Seattle, WA 98109-1024, USA.
FAU - Deeg, H Joachim
AU  - Deeg HJ
LA  - eng
GR  - CA18029/CA/NCI NIH HHS/United States
GR  - CA87948/CA/NCI NIH HHS/United States
GR  - HL36444/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
SB  - IM
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Myelodysplastic Syndromes/*surgery
MH  - Myeloproliferative Disorders/*surgery
EDAT- 2006/06/20 09:00
MHDA- 2006/09/29 09:00
CRDT- 2006/06/20 09:00
PHST- 2006/06/20 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2006/06/20 09:00 [entrez]
AID - S1521-6926(05)00096-4 [pii]
AID - 10.1016/j.beha.2005.07.009 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2006;19(3):519-33. doi: 10.1016/j.beha.2005.07.009.